These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38970270)
1. Effect of metformin on gut microbiota imbalance in patients with T2DM, and the value of probiotic supplementation. Li L; Chen Y; Tang Z; You Y; Guo Y; Liao Y Allergol Immunopathol (Madr); 2024; 52(4):84-90. PubMed ID: 38970270 [TBL] [Abstract][Full Text] [Related]
2. Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study. Gao Y; Zhao T; Lv N; Liu S; Yuan T; Fu Y; Zhao W; Zhu B Endocrine; 2024 Sep; 85(3):1178-1192. PubMed ID: 38761345 [TBL] [Abstract][Full Text] [Related]
3. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study. Palacios T; Vitetta L; Coulson S; Madigan CD; Lam YY; Manuel R; Briskey D; Hendy C; Kim JN; Ishoey T; Soto-Giron MJ; Schott EM; Toledo G; Caterson ID Nutrients; 2020 Jul; 12(7):. PubMed ID: 32660025 [TBL] [Abstract][Full Text] [Related]
4. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590 [TBL] [Abstract][Full Text] [Related]
5. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9]. Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058 [TBL] [Abstract][Full Text] [Related]
6. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. Chen P; Huang Q; Xu XJ; Shao ZL; Huang LH; Yang XZ; Guo W; Li CM; Chen C Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):349-54. PubMed ID: 27143183 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels. Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290 [TBL] [Abstract][Full Text] [Related]
8. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343 [TBL] [Abstract][Full Text] [Related]
9. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. Tong X; Xu J; Lian F; Yu X; Zhao Y; Xu L; Zhang M; Zhao X; Shen J; Wu S; Pang X; Tian J; Zhang C; Zhou Q; Wang L; Pang B; Chen F; Peng Z; Wang J; Zhen Z; Fang C; Li M; Chen L; Zhao L mBio; 2018 May; 9(3):. PubMed ID: 29789365 [TBL] [Abstract][Full Text] [Related]
10. Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Wang X; Chen L; Zhang C; Shi Q; Zhu L; Zhao S; Luo Z; Long Y Front Endocrinol (Lausanne); 2024; 15():1392306. PubMed ID: 39114293 [TBL] [Abstract][Full Text] [Related]
11. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630 [TBL] [Abstract][Full Text] [Related]
12. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839 [TBL] [Abstract][Full Text] [Related]
13. Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients. Niu X; Wang Y; Huang L; Guo P; Zhang S; Sun Y; Jin M Front Endocrinol (Lausanne); 2024; 15():1397034. PubMed ID: 39257903 [TBL] [Abstract][Full Text] [Related]
14. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity. Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052 [TBL] [Abstract][Full Text] [Related]
15. Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. Sun Y; Yu Q; Xie J Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):21-28. PubMed ID: 33040780 [TBL] [Abstract][Full Text] [Related]
16. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949 [TBL] [Abstract][Full Text] [Related]
17. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Derosa G; D'Angelo A; Romano D; Maffioli P Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078 [TBL] [Abstract][Full Text] [Related]
18. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750 [TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus. Ma J; Fu J; Guo N; Liu Z Altern Ther Health Med; 2024 Aug; 30(8):144-151. PubMed ID: 38294744 [TBL] [Abstract][Full Text] [Related]
20. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial. Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]